Yara Abdou, MD

Articles

Exciting Ongoing Studies in the Treatment of HR+, HER2- Metastatic Breast Cancer

February 23rd 2024

The doctors recommend using endocrine therapy-based options first-line when possible, before considering chemotherapy or antibody-drug conjugates, in order to preserve quality of life; they note exceptions could include patients with rapid progression or visceral crisis where immediate chemotherapy may be warranted, and that determining optimal sequencing requires understanding the safety profiles and efficacy data for the available regimens.

Approaches to Treatment Decision-Making and Sequencing for HR+, HER2- Metastatic Breast Cancer

February 16th 2024

The doctors recommend using endocrine therapy-based options first-line when possible, before considering chemotherapy or antibody-drug conjugates, in order to preserve quality of life; they note exceptions could include patients with rapid progression or visceral crisis where immediate chemotherapy may be warranted, and that determining optimal sequencing requires understanding the safety profiles and efficacy data for the available regimens.

The TROPION-Breast01 Trial: Datopotamab Deruxtecan in HR+, HER2- Breast Cancer

February 16th 2024

The TROPION-Breast01 trial studied the antibody-drug conjugate datopotamab deruxtecan (Dato-DXd) in previously treated HR+, HER2- breast cancer patients and showed improved progression-free survival to 7 months compared to 4.5 months with standard chemotherapy, with less high grade toxicity observed with Dato-DXd.

The EMERALD Trial: Elacestrant in Patients with HR+, HER2- Advanced Breast Cancer

February 9th 2024

The EMERALD study showed improved progression-free survival with elacestrant compared to standard endocrine therapy in patients with ESR1 mutations who progressed on prior AI and CDK4/6 inhibitors, with the greatest benefit in those having longer duration of response to first-line therapy.

CAPItello-291 Trial: Evaluating Capivasertib Plus Fulvestrant in Patients With HR+, HER2- Advanced Breast Cancer

February 9th 2024

Laura Huppert, MD, and Yara Abdou, MD, discuss the CAPItello-291 trial which looked at the efficacy of capivasertib, a small molecule AKT inhibitor, in combination with fulvestrant for patients with estrogen receptor positive, HER2 negative advanced breast cancer who had progressed on prior endocrine therapy.

Approaches to Repeat Hormone Receptor and HER2 Status Testing Before Initiating Later Lines of Therapy

February 2nd 2024

Laura Huppert, MD, and Yara Abdou, MD, review approaches to repeat hormone receptor and HER2 status testing before initiating later lines of therapy in patients with metastatic breast cancer.

The MAINTAIN Trial: Ribociclib in Combination With Endocrine Therapy in Patients With Metastatic Breast Cancer

February 2nd 2024

Laura Huppert, MD, and Yara Abdou, MD, discuss data from the MAINTAIN trial on ribociclib in combination with endocrine therapy in patients with metastatic breast cancer.

Overview of the Treatment Landscape for HR+, HER2- Advanced or Metastatic Breast Cancer

February 2nd 2024

Laura Huppert, MD, and Yara Abdou, MD, provide an overview of the treatment landscape for HR+, HER2- advanced or metastatic breast cancer.

An Overview of HR+, HER2- Metastatic Breast Cancer

December 18th 2023

Experts provides an overview of HR-positive , HER2-negative metastatic breast cancer and current treatment approaches.

Dr Abdou on Sequencing CDK4/6 Inhibitors in HER2– Metastatic Breast Cancer

November 16th 2023

Yara Abdou, MD, discusses findings from the phase 2 MAINTAIN trial in patients with HER2-negative metastatic breast cancer, as well as the clinical implications of these trial results.

Dr Abdou on Treatment Sequencing With CDK4/6 Inhibitors in HR+/HER2– Breast Cancer

August 4th 2023

Yara Abdou, MD, discusses treatment sequencing with CDK4/6 inhibitors across all lines of therapy in patients with hormone receptor–positive, HER2-negative breast cancer.

Dr Abdou on Considerations Between AKT vs PI3K Inhibition in HR+/HER2– Breast Cancer

August 2nd 2023

Yara Abdou, MD, discusses the considerations between AKT inhibitors vs PI3K inhibition in patients with hormone receptor-positive, HER2-negative breast cancer.

Dr Abdou on Treatment Updates From the 2023 ASCO Annual Meeting in HR+/HER2– Breast Cancer

July 31st 2023

Yara Abdou, MD, discusses updates in the treatment of patients with HR-positive, HER2-negative breast cancer.

Dr. Abdou on Race and Clinical Outcomes in Breast Cancer

December 7th 2022

Yara Abdou, MD, discusses racial disparities in breast cancer outcomes in patients enrolled to the phase 3 RxPONDER trial.

Dr. Abdou on the Significance of the DESTINY-Breast03 Trial in HER2-Positive Breast Cancer

February 21st 2022

Yara Abdou, MD, discusses the significance of the phase 3 DESTINY-Breast03 trial in HER2-positive breast cancer.

SABCS 2021: Novel Approaches to Breast Cancer Management

January 24th 2022

After discussing a few more key datasets from the SABCS 2021 Virtual Meeting, expert panelists discuss how they would approach treatment in several subsets of breast cancer.

SABCS 2021: Brain Metastases Updates in Breast Cancer

January 24th 2022

Focusing on datasets from the SABCS 2021 Virtual Meeting, panelists consider novel approaches to the management of brain metastases in breast cancer.

SABCS 2021: Updates in Metastatic Breast Cancer

January 24th 2022

Expert panelists share their perspectives on metastatic breast cancer management datasets from the SABCS 2021 Virtual Meeting.

Even Superheroes Can Burn Out in Oncology

August 24th 2019

Yara Abdou, MD, sheds light on the challenging path of becoming an oncologist.